You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
外电引述世卫文件指 WTO专家对国药集团疫苗部分副作用数据信心十分低
阿思达克 05-06 12:23
据《路透》引述一份文件指,,世卫(WHO)专家对内地国药集团新冠疫苗(BBIBP-CorV)就一些疫苗接种者呈现副作用的数据信心十分低(very low confidence),但对疫苗保护效能整体而言有信心。

世卫免疫战略谘询专家组(SAGE)就国药疫苗本周评估所准备的证据评核,涵盖45个国家及司法管辖区成年人,及6,500万剂已接种疫苗。专家审视有关数据,并就疫苗相关政策提供建议。

文件显示,在完成接种两剂疫苗後,多国第三阶段临床测试的有效率是78.1%,略低於中国早前公布的79.34%。文件指,对18至59岁成年人而言,非常有信心完成两剂疫苗接种後,可预防感染新冠病毒。

不过,文件补充,就参与者共病症与并发症进行安全分析有限,源於第三阶段临床测试出现共病症与并发症的参与者数量较少。

文件指出,对60岁以上长者接种一至两剂国药疫苗後出现严重副作用风险的证据质素,信心十分低。文件进一步称,对有共病症与并发症、有健康特别状况的个人接种一至两剂国药疫苗後出现严重副作用风险的证据质素,信心十分低。

据《路透》报道,美国总统拜登屈服於美国民主党议员及其他百多个国家的压力,转(车太)支持放弃新冠病毒疫苗知识产权专利,消息导致隔晚美国疫苗股受压。消息夹击下,国药集团旗下国药控股(01099.HK)今早(6日)低开1.6%报25.35元後,跌幅随即扩大,早市曾跌15.2%,低见21.85元,半日收跌10.1%,报23.15元,成交2,982万股,涉逾6.96亿元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account